Status:

COMPLETED

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

Lead Sponsor:

Targacept Inc.

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

55-80 years

Phase:

PHASE1

Brief Summary

This is a Phase 1 study to examine the safety, tolerability and pharmacokinetics of TC-5619 in elderly subjects with and without Alzheimer's disease. Group 1 includes elderly subjects with Alzheimer's...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (Groups 1 \& 2):
  • Normal body mass index (BMI)
  • Non-smoking for a minimum of 3 months
  • Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG.
  • Group 1 Only:
  • Subjects a Mini Mental State Examination score between 12-22, inclusive.
  • Diagnosis of probable Alzheimer's Disease according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
  • Subjects must have a reliable caregiver.
  • Exclusion Criteria (Groups 1 \& 2):
  • Subjects with clinically significant heart disease, pulmonary disease, diabetes, neurologic or psychiatric disease (Group 1 subjects must have Alzheimer's Disease), or any other illness that could interfere with interpretation of study results.
  • Subjects with a past or current history of seizures cannot participate.
  • Current use of donepezil, rivastigmine or galantamine.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2011

    Estimated Enrollment :

    38 Patients enrolled

    Trial Details

    Trial ID

    NCT01254448

    Start Date

    September 1 2010

    End Date

    May 1 2011

    Last Update

    September 4 2013

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    Collaborative Neuroscience Network

    Long Beach, California, United States, 90806

    2

    San Francisco Clinical Research Center

    San Francisco, California, United States, 94109

    3

    MD Clinical

    Hallandale, Florida, United States, 33009

    4

    Galiz Research

    Miami Springs, Florida, United States, 33166